KR20230019109A - Akt3 조절제 및 이의 사용 방법 - Google Patents

Akt3 조절제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20230019109A
KR20230019109A KR1020227042831A KR20227042831A KR20230019109A KR 20230019109 A KR20230019109 A KR 20230019109A KR 1020227042831 A KR1020227042831 A KR 1020227042831A KR 20227042831 A KR20227042831 A KR 20227042831A KR 20230019109 A KR20230019109 A KR 20230019109A
Authority
KR
South Korea
Prior art keywords
alkyl
cycloalkyl
akt3
aryl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227042831A
Other languages
English (en)
Korean (ko)
Inventor
사미르 클레이프
미카옐 므크르티치안
Original Assignee
조지아뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조지아뮨 엘엘씨 filed Critical 조지아뮨 엘엘씨
Publication of KR20230019109A publication Critical patent/KR20230019109A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Amplitude Modulation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227042831A 2020-05-08 2021-05-07 Akt3 조절제 및 이의 사용 방법 Pending KR20230019109A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021797P 2020-05-08 2020-05-08
US63/021,797 2020-05-08
PCT/US2021/031372 WO2021226510A2 (en) 2020-05-08 2021-05-07 Akt3 modulators and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20230019109A true KR20230019109A (ko) 2023-02-07

Family

ID=78468492

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227042831A Pending KR20230019109A (ko) 2020-05-08 2021-05-07 Akt3 조절제 및 이의 사용 방법

Country Status (12)

Country Link
US (1) US20230181563A1 (https=)
EP (1) EP4146196A4 (https=)
JP (1) JP2023525758A (https=)
KR (1) KR20230019109A (https=)
CN (1) CN115956078A (https=)
AU (1) AU2021269065A1 (https=)
BR (1) BR112022022327A2 (https=)
CA (1) CA3182675A1 (https=)
IL (1) IL297596A (https=)
MX (1) MX2022014019A (https=)
PH (1) PH12022553026A1 (https=)
WO (1) WO2021226510A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525757A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター
AU2021266786A1 (en) * 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4993838B2 (ja) * 2000-08-11 2012-08-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ｐ３８のインヒビターとしてのピリジン誘導体
ATE461179T1 (de) * 2003-04-24 2010-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
WO2008046085A2 (en) * 2006-10-12 2008-04-17 Supergen, Inc. Quinoline derivatives for modulating dna methylation
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7939546B2 (en) * 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7790746B2 (en) * 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
US9707278B2 (en) * 2014-04-17 2017-07-18 Augusta University Research Institute, Inc. Methods of modulating immune responses by modifying Akt3 bioactivity
US10292978B2 (en) * 2016-01-15 2019-05-21 Augusta University Research Institute, Inc. Specific Akt3 inhibitor and uses thereof
US10342868B2 (en) * 2016-01-15 2019-07-09 Augusta University Research Institute, Inc. Methods and compositions for inhibiting Akt3
CN110366749A (zh) * 2017-06-29 2019-10-22 惠普发展公司，有限责任合伙企业 可操作来具有充当主显示器的区域和充当辅显示器的区域的连续平面显示器
MX2020002611A (es) * 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.

Also Published As

Publication number Publication date
CA3182675A1 (en) 2021-11-11
WO2021226510A9 (en) 2022-01-13
BR112022022327A2 (pt) 2023-01-03
WO2021226510A3 (en) 2021-12-16
JP2023525758A (ja) 2023-06-19
MX2022014019A (es) 2023-02-16
US20230181563A1 (en) 2023-06-15
IL297596A (en) 2022-12-01
AU2021269065A1 (en) 2022-12-15
CN115956078A (zh) 2023-04-11
EP4146196A4 (en) 2024-06-26
EP4146196A2 (en) 2023-03-15
PH12022553026A1 (en) 2024-05-13
WO2021226510A2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
KR102917509B1 (ko) 특이적 akt3 활성제 및 이의 용도
JP2021523110A (ja) 遺伝子発現のためのナノ粒子及びその使用
CN109414441A (zh) 治疗医学障碍的喹唑啉和吲哚化合物
JP7683932B2 (ja) ナチュラルキラー細胞を刺激するための組成物及び方法
US20240010976A1 (en) Methods and compositions for stimulating gamma delta t cells
US11291719B2 (en) Methods and compositions for modulating Akt3
RS60181B1 (sr) Terapeutska upotreba morfogenetskih proteina kosti
US20210196817A1 (en) Compositions and Methods for Selectively Modulating Tregs
US9707278B2 (en) Methods of modulating immune responses by modifying Akt3 bioactivity
KR20230019109A (ko) Akt3 조절제 및 이의 사용 방법
CN115552013A (zh) 修饰的微核小体核心蛋白及其在核酸递送中的用途
JP2019534300A (ja) プログラム細胞死リガンド１の腸管発現
JP2022522843A (ja) エピジェネティック調節と免疫チェックポイント遮断の組み合わせのための薬物送達
HK40084846A (en) Akt3 modulators and methods of use thereof
US20210130782A1 (en) Engineered Exosomes to Detect and Deplete Pro-Tumorigenic Macrophages
RU2815372C2 (ru) Специфический активатор akt3 и его применение
TW202220974A (zh) 用於調節ａｋｔ３的方法及組合物
HK40033083B (en) Specific akt3 activator and uses thereof
HK40033083A (en) Specific akt3 activator and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000